Human Papillomavirus Infections Pipeline Analysis

Description: Currently there is significant amount of research being undertaken to study the process of HPV infection causing precancerous changes in normal cells. Also, methods to prevent and manage this situation are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has been extended to other tissues also in which HPV may cause cancer, such as the oropharynx and anus. Also, many organizations are analyzing the use of second-generation preventive vaccines along with therapeutic HPV vaccines, which could possibly prevent the development of cancer among women previously infected with HPV. Such an “ideal” vaccine strategy would combine a preventive and therapeutic vaccine, which would help in a major way.

The mechanism of the HPV vaccines is similar to the other immunizations which help in protecting against viral infections. It has been observed and analyzed that the unique surface components of HPV have the capability to create an antibody response which could possibly protect the human body against infection. These components could thus be used as a basis of the vaccine. There are only 2 HPV vaccines which are currently marketed across the globe. Both these vaccines are prepared using the recombinant technology, which is taken from purified L1 structural proteins which self assemble to form HPV type-specific empty shells or virus-like particles (VLPs).

Since there are no therapeutic HPV vaccines available at present which have proved their efficiency in the clinical trials, there is still a lot of work which is required in this field, thus opening a large window of opportunities. There have been some technological advancements in the past 4-5 years. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and efficient vaccines, with the help of adequate funding. Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future. Thus, there needs to be more focus being given to increasing the knowledge and awareness about HPV infections and the ways and methods to treat it, either through drugs or through vaccines.

Human Papillomavirus Infections Vaccine Pipeline Analysis - Report Highlights:

- Human Papillomavirus Vaccine Market Overview
- Marketed Drug Profiles & Patent Analysis
- Clinical Trial Insight by Phase & Country
- Drug Clinical Development Phase: 47
- Suspended & Discontinued Drug Profiles: 46
- Competitive Landscape

Contents:

1. Global Human Papillomavirus Infection Drug Market Overview
   1.1 Market Overview
   1.2 Clinical Pipeline Insight

2. Human Papillomavirus Infections Drug Clinical Trial Insight by Phase & Country
   2.1 Unknown Phase
   2.2 Research
   2.3 Preclinical
   2.4 Clinical
   2.5 Phase-0
   2.6 Phase-I
   2.7 Phase-I/II
   2.8 Phase-II
   2.9 Phase-II/III
   2.10 Phase-III

3. Marketed Human Papillomavirus Drug Profile
   3.1 Gardasil
3.2 Cervarix
3.3 Zyclara
3.4 Intron A
3.5 Yallaferon
3.6 ReliFeron
3.7 Alferon N
3.8 Veregen/Polyphenon E
3.9 Dermojuventus

4. No Development Reported & Discontinued HPV Drug Profiles
4.1 No Development Reported
4.2 Discontinued
4.3 Market Withdrawal

5. Competitive Landscape
5.1 Advanced Viral Research
5.2 Biogen Idec
5.3 BioSphings
5.4 EyeGene
5.5 Helix BioPharma
5.6 Inviragen
5.7 Medimmune
5.8 Merck & Co
5.9 Valeant Pharmaceuticals

Tables
- Drug Profile Overview
- Active Indication
- Phase of Development
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class

Figures:
Figure 1- 1: HPV Infections Clinical Pipeline by Phase (%), 2014
Figure 1- 2: HPV Infections Clinical Pipeline by Phase (Number), 2014
Figure 1- 3: No Development Reported in HPV Infections Clinical Pipeline by Phase (%), 2014
Figure 1- 4: No Development Reported in HPV Infections Clinical Pipeline by Phase (Number), 2014
Figure 1- 5: Discontinued HPV Infections Clinical Pipeline by Phase (%), 2014
Figure 1- 6: Discontinued HPV Infections Clinical Pipeline by Phase (Number), 2014

Ordering:  
Order Online - http://www.researchandmarkets.com/reports/2871845/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

| Product Name: | Human Papillomavirus Infections Pipeline Analysis |
| Web Address:  | http://www.researchandmarkets.com/reports/2871845/ |
| Office Code:  | SCBR37DT |

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 1800</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
</tr>
<tr>
<td>CD-ROM:</td>
<td>USD 2100 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Hard Copy:</td>
<td>USD 2400 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 3600</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td>________________________________</td>
</tr>
<tr>
<td>Email Address:</td>
<td>* ______________________________</td>
</tr>
<tr>
<td>Job Title:</td>
<td>________________________________</td>
</tr>
<tr>
<td>Organisation:</td>
<td>________________________________</td>
</tr>
<tr>
<td>Address:</td>
<td>________________________________</td>
</tr>
<tr>
<td>City:</td>
<td>________________________________</td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td>____________________________</td>
</tr>
<tr>
<td>Country:</td>
<td>________________________________</td>
</tr>
<tr>
<td>Phone Number:</td>
<td>________________________________</td>
</tr>
<tr>
<td>Fax Number:</td>
<td>________________________________</td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:
Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World